Literature DB >> 11916974

Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37.

Giuliano Siligardi1, Barry Panaretou, Philippe Meyer, Shradha Singh, Derek N Woolfson, Peter W Piper, Laurence H Pearl, Chrisostomos Prodromou.   

Abstract

In vivo activation of client proteins by Hsp90 depends on its ATPase-coupled conformational cycle and on interaction with a variety of co-chaperone proteins. For some client proteins the co-chaperone Sti1/Hop/p60 acts as a "scaffold," recruiting Hsp70 and the bound client to Hsp90 early in the cycle and suppressing ATP turnover by Hsp90 during the loading phase. Recruitment of protein kinase clients to the Hsp90 complex appears to involve a specialized co-chaperone, Cdc37p/p50(cdc37), whose binding to Hsp90 is mutually exclusive of Sti1/Hop/p60. We now show that Cdc37p/p50(cdc37), like Sti1/Hop/p60, also suppresses ATP turnover by Hsp90 supporting the idea that client protein loading to Hsp90 requires a "relaxed" ADP-bound conformation. Like Sti1/Hop/p60, Cdc37p/p50(cdc37) binds to Hsp90 as a dimer, and the suppressed ATPase activity of Hsp90 is restored when Cdc37p/p50(cdc37) is displaced by the immunophilin co-chaperone Cpr6/Cyp40. However, unlike Sti1/Hop/p60, which can displace geldanamycin upon binding to Hsp90, Cdc37p/p50(cdc37) forms a stable complex with geldanamycin-bound Hsp90 and may be sequestered in geldanamycin-inhibited Hsp90 complexes in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11916974     DOI: 10.1074/jbc.M201287200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  106 in total

1.  A chemical cross-linking method for the analysis of binding partners of heat shock protein-90 in intact cells.

Authors:  Shaoming Song; Sutapa Kole; Michel Bernier
Journal:  Biotechniques       Date:  2012-04       Impact factor: 1.993

Review 2.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights.

Authors:  Mikko Taipale; Daniel F Jarosz; Susan Lindquist
Journal:  Nat Rev Mol Cell Biol       Date:  2010-06-09       Impact factor: 94.444

3.  Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.

Authors:  Hardik J Patel; Shanu Modi; Gabriela Chiosis; Tony Taldone
Journal:  Expert Opin Drug Discov       Date:  2011-05       Impact factor: 6.098

Review 4.  Cdc37 goes beyond Hsp90 and kinases.

Authors:  Morag MacLean; Didier Picard
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

5.  Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery.

Authors:  Philippe Meyer; Chrisostomos Prodromou; Chunyan Liao; Bin Hu; S Mark Roe; Cara K Vaughan; Ignacija Vlasic; Barry Panaretou; Peter W Piper; Laurence H Pearl
Journal:  EMBO J       Date:  2004-01-22       Impact factor: 11.598

6.  CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37.

Authors:  Yoshihiko Miyata; Eisuke Nishida
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

7.  Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine.

Authors:  Wanping Xu; Mehdi Mollapour; Chrisostomos Prodromou; Suiquan Wang; Bradley T Scroggins; Zach Palchick; Kristin Beebe; Marco Siderius; Min-Jung Lee; Anthony Couvillon; Jane B Trepel; Yoshihiko Miyata; Robert Matts; Len Neckers
Journal:  Mol Cell       Date:  2012-06-21       Impact factor: 17.970

Review 8.  Chaperone machines for protein folding, unfolding and disaggregation.

Authors:  Helen Saibil
Journal:  Nat Rev Mol Cell Biol       Date:  2013-09-12       Impact factor: 94.444

9.  Hsp90 cochaperone Aha1 is a negative regulator of the Saccharomyces MAL activator and acts early in the chaperone activation pathway.

Authors:  Fulai Ran; Nidhi Gadura; Corinne A Michels
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

Review 10.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.